Valeant, Under Pressure About Price Increases, Plans Changes
Valeant Pharmaceuticals International Inc. is a Canada-based company that develops and markets medications used in neurology, dermatology, and infectious diseases. As of late, the company has come under scrutiny for its practice acquiring “mispriced assets,” or drugs whose prices can be increased to maximize profit for the company. In response to pressure, which includes subpoenas from the federal government, the company is making plans to revise its business model. The article discusses some of the company’s financial conflicts during this time.